Gene Editing Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Component, Technology, Application, End User, and Geography

The gene editing market size is expected to grow from US$ 6.542 billion in 2022 to US$ 23.902 billion by 2030; it is estimated to record a CAGR of 17.6% during 2022-2030.

The growth of the gene editing market is attributed to the increase in cancer and other genetic disorders and growing investment in genetic research. However, the high cost of genomic equipment hinders the market growth.

Personalized medicine is the field that utilizes patients' genetic and environmental data to deliver optimal healthcare. It is based on the principle that every patient is unique and requires individualistic pharmacological treatment. Since it is a rapidly evolving area, it is presently incorporated into several healthcare systems. The ability to make precise changes in the genome opens new possibilities for developing targeted therapies and personalized medicine. Gene editing is crucial in personalized medicine by tailoring medical treatments to individual patients based on their genetic information. It offers various applications in the field. Firstly, gene editing techniques like CRISPR-Cas9 enable the correction or modification of specific genes associated with genetic disorders, potentially providing treatments or cures for conditions such as cystic fibrosis and other genetic disorders. Secondly, gene editing aids in pharmacogenomics, allowing researchers to study how an individual's genetic variation impacts their medication response. This knowledge helps in developing personalized treatment plans and optimizing drug dosage.

Gene editing has also shown promise in personalized cancer therapy, where immune cells can be edited to better target and destroy cancer cells. Furthermore, gene editing can contribute to preventing and treating infectious diseases by enhancing immune cell recognition and modifying pathogens. It also facilitates disease modeling and drug development by creating accurate disease models, enabling researchers to understand diseases better and develop personalized treatment approaches. These applications demonstrate the potential of gene editing in advancing personalized medicine, enabling tailored treatments specific to an individual genetic profile. Gene editing in personalized medicine is still advancing, and further research and clinical trials are needed to ensure safety and efficacy.

The growing need for personalized medicine is one of the main factors propelling the growth of the gene editing market. Gene editing technology makes customized therapies and treatments based on an individual's genetic composition possible. In July 2021, the US FDA authorized one patient to receive a tailored CRISPR-based gene therapy for their mutation. The Boston non-profit Cure Rare Disease initiated the clinical trial, which marked numerous milestones, including the first-ever personalized CRISPR therapy and the first clinical trial to implement any form of gene editing for muscular dystrophy treatment.

Increased patient well-being, fewer adverse effects, and better treatment outcomes are all possible with this personalized approach to medicine. The demand for targeted therapeutics and the increasing understanding of personalized medicine have been major factors in the uptake and development of gene editing technology. The growing number of gene therapy candidates in the development pipeline highlights the potential for transformative breakthroughs in personalized medicine and treating previously incurable diseases, favoring market growth.

The cost of production is determined by the packages of genome editing for different applications offered by different players. The costs associated with gene editing equipment can be substantial. Gene editing technologies like CRISPR-Cas9 require specialized laboratory equipment, including DNA sequencers, thermal cyclers, fluorescence microscopes, and electroporation devices. These instruments have a high price tag, ranging from thousands to millions of dollars. The US Food and Drug Administration (FDA) has authorized four gene treatments. Kymriah and Yescarta are two chimeric antigen receptor (CAR T-cell) treatments. Yescarta costs US$ 373,000 in the market, whereas Kymriah costs between US$ 373,000 and US$ 475,000, depending on the kind of cancer. The FDA licensed Luxturna in 2017 to treat a rare kind of inherited blindness that affects 1,000 to 2,000 people in the US. The cost of this procedure is US$ 425,000 per eye. Zolgensma was licensed in 2020 to treat a rare childhood condition called spinal muscular atrophy in children under the age of two. Per patient, a single intravenous injection costs US$ 2.1 million. The cost of production is increased based on the procedures added during the production.

In addition, additional challenges and costs are associated with the validation and evaluation of genome editing methods. If the validation shows negative results, repetitive procedures are performed, and hundreds and thousands of dollars are spent on the same procedures. Thus, out of the total cost incurred in the production of genome editing, two-thirds is spent on validation. Hence, the cost of production is among the primary factors restraining the market's growth.

Components-Based Insights

Based on components, the gene editing market is segmented into reagents and consumables, software and systems, and services. The services segment dominated with the largest share of the market in 2022. However, the reagents and consumables segment is anticipated to register the highest CAGR from 2022 to 2030.

The International Agency for Research on Cancer and the World Health Organization (WHO) are among the primary and secondary sources referred to while preparing the gene editing market report.